# A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

> **NCT04903093** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 19 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Abrocitinib tablet
- **DRUG:** Abrocitinib Suspension F1
- **DRUG:** Abrocitinib Suspension F2
- **DRUG:** Abrocitinib Suspension F3
- **DRUG:** Abrocitinib Suspension F4
- **DRUG:** Abrocitinib Suspension F5
- **DRUG:** Abrocitinib Suspension F6
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT04903093
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-04
- **Primary completion:** 2021-10-26
- **Final completion:** 2021-10-26
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903093, "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04903093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*